NCT05539729View on ClinicalTrials.gov

Vancomycin Study in Multiple Sclerosis (MS)

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
Multiple Sclerosis
Interventions
DRUG

Vancomycin

A marketed antibiotic (Study Drug) supplied by Amerisource Bergen, by the Mount Sinai Investigational Drug Services (IDS), and encapsulated in red coating to match the placebo.

DRUG

Placebo

Placebo created by the IDS and encapsulated in red coating to match the Study Drug.

Trial Locations (1)

10029

RECRUITING

Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New York

All Listed Sponsors
collaborator

Doris Duke Charitable Foundation

OTHER

lead

Icahn School of Medicine at Mount Sinai

OTHER